- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Mental health plans are affordable
Even the least generous health plans can afford unlimited mental health care coverage, according to a new study funded and released by the National Institute of Mental Health.
Even the least generous health plans can afford unlimited mental health care coverage, according to a new study funded and released by the National Institute of Mental Health.
The study examined 1995 and 1996 claims data from 24 managed care health care plans that provide mental health care through an independent vendor or subsidiary. Even those with the least generous coverage - 30 days of inpatient care and 20 outpatient sessions - incurred an increase of only $7 per enrollee per year in plans with minimal copayments and no deductibles.
That amount is less than half of one percent of the annual cost per enrollee of an average managed care plan. The average managed care health plan spends approximately $1,500 to $2,000 per enrollee.
According to the Mental Health Parity Act, which went into effect Jan. 1, 1998, employers who offer mental health benefits must provide dollar limits equal to those for other medical benefits unless they can prove that their health care costs would increase by 1% or more.
A full report of the study was published in the Nov. 12 issue of the Journal of the American Medical Association. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
